Lithium-responsive affective disorders: no association with the tyrosine hydroxylase gene

Psychiatry Res. 1996 Sep 27;64(2):91-6. doi: 10.1016/0165-1781(96)02888-0.

Abstract

Family, adoption, and twin studies have demonstrated the involvement of genetic factors in the etiology of major affective disorders. In an attempt to identify the involved genes, several linkage and association studies have focused on the gene coding for tyrosine hydroxylase, the rate-limiting enzyme in catecholamine synthesis. The discrepant results to date could be explained by etiological heterogeneity, which may be substantially reduced by selecting patients according to lithium response. Therefore, we investigated 54 patients who had shown definite long-term response to lithium monotherapy in spite of a high risk of recurrence as indicated by the previous clinical course. All the subjects suffered from major affective disorder by Research Diagnostic Criteria (48 bipolar, 6 recurrent unipolar). They were compared to 94 population controls of similar ethnic background to test for association with a penta-allelic microsatellite marker found within the tyrosine hydroxylase gene. No significant differences in allele and genotype frequencies were observed between the two groups, providing further evidence against a major role for the tyrosine hydroxylase gene in the etiology of major affective disorders.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Alleles
  • Antidepressive Agents / administration & dosage
  • Antidepressive Agents / therapeutic use*
  • Chromosomes, Human, Pair 11
  • Female
  • Genotype
  • Humans
  • Lithium / administration & dosage
  • Lithium / therapeutic use*
  • Male
  • Middle Aged
  • Mood Disorders / drug therapy*
  • Mood Disorders / genetics*
  • Tyrosine 3-Monooxygenase / genetics*

Substances

  • Antidepressive Agents
  • Lithium
  • Tyrosine 3-Monooxygenase